Immunotherapy plus chemotherapy for newly diagnosed B-cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 15 and 65 years old
- Newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) that is Philadelphia chromosome-negative
- No prior cancer treatment (except short-term steroid or hydroxyurea use)
- Adequate liver and kidney function (can process medications safely)
- Able to understand the study and give written consent
- Not pregnant or breastfeeding, and no serious heart disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that uses blinatumomab (a drug that helps your immune system attack leukemia cells) combined with your own stem cell transplant. It is for people with B-ALL who cannot or choose not to have a transplant from another person.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
This trial tests a CAR-T cell therapy for adults who have just been diagnosed with a type of leukemia called Ph+ B-cell ALL. The treatment uses specially engineered immune cells to target and destroy cancer cells that have a specific marker (CD19 and CD22) and the Philadelphia chromosome. It may be an option for those who have not yet started standard chemotherapy.
This trial tests giving chemotherapy together with a special immune cell treatment called CAR-T cells for adults who have just been diagnosed with a specific type of leukemia (Ph- B-ALL). The goal is to see if this combination works better than standard treatment.
This trial tests a combination of low-intensity chemotherapy and a short course of blinatumomab (a targeted immunotherapy) in adults with a certain type of acute leukemia. The goal is to see if this approach helps prepare patients for a stem cell transplant with fewer side effects.
Hear when a new B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.